AKT1 and cancer: There are results also demonstrate that combination of CK2 inhibitor CX-4945 with erlotinib (EGFR tyrosine kinase inhibitor) results in synergistic killing of cancer cells by attenuating the PI3K-Akt-mTOR pathway [43].